Abstract
In their recent Review paper in The Lancet Oncology, Gert De Meerleer and colleagues take a comprehensive look at evidence for pelvic irradiation in patients with prostate cancer.1 Specifically, for clinically node-negative prostate cancer, the value of elective whole pelvic radiotherapy (WPRT) has been discussed at length. For patients with Roach nodal risk of at least 20%, the POP-RT trial showed significant improvement in biochemical control, disease-free survival, and metastasis-free survival with WPRT.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
